A specific type of immune cell (Th17) and its chemical signal (IL-17) are essential for the body to clear the Pneumocystis fungus from the lungs — without them, the infection gets much worse.
Claim Context
Th17 cells and their signature cytokine IL-17A are critical for controlling Pneumocystis fungal burden, as depletion of IL-17 leads to a 36-fold increase in fungal load and delayed clearance in mouse models, indicating a non-redundant role in antifungal defense.
“IL‐17 depletion leads to delayed elimination of Pneumocystis and worsened pulmonary damage in comparison with observations in WT PCP mice... WT mice treated with anti‐IL‐17 antibodies showed a 36‐fold increase in fungal burden 3 weeks after Pneumocystis inoculum.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether enhancing IL-17 signaling improves fungal clearance in immunocompromised humans with PCP.
A double-blind, placebo-controlled trial of 120 immunocompromised patients with confirmed PCP, randomized to receive recombinant IL-17A (10 µg/kg IV weekly) or placebo for 4 weeks, with primary outcome of fungal burden reduction in BAL fluid by qPCR at day 14.
Whether endogenous IL-17 levels correlate with fungal clearance rates and clinical outcomes in human PCP.
A prospective cohort of 150 immunocompromised patients with PCP, measuring serial IL-17A levels in BAL fluid and serum, correlating with fungal burden (qPCR), oxygenation, and time to clearance, adjusting for CD4+ count and comorbidities.
Whether patients with genetic defects in the IL-23/IL-17 axis have increased susceptibility to PCP.
A matched case-control study comparing 50 PCP patients with 100 controls, screening for mutations in IL12B, IL23R, RORC, and STAT3 genes, and assessing PCP incidence in carriers vs non-carriers.
Whether IL-17 levels are elevated in the lungs of patients with active PCP compared to those with colonization or no infection.
A cross-sectional analysis of BAL fluid from 60 patients: 20 with active PCP, 20 with Pneumocystis colonization, and 20 with other interstitial lung diseases, measuring IL-17A by ELISA and Th17 cell frequency by flow cytometry.
Clinical presentation of PCP in patients with known IL-17 pathway deficiencies.
A case series of 5 patients with RORC or IL12B mutations who develop PCP, documenting clinical course, BAL cytokine profiles, and T-cell responses.